Carol Wysham

4.6k total citations · 2 hit papers
77 papers, 3.1k citations indexed

About

Carol Wysham is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Carol Wysham has authored 77 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Endocrinology, Diabetes and Metabolism, 25 papers in Surgery and 17 papers in Molecular Biology. Recurrent topics in Carol Wysham's work include Diabetes Treatment and Management (68 papers), Diabetes Management and Research (58 papers) and Pancreatic function and diabetes (23 papers). Carol Wysham is often cited by papers focused on Diabetes Treatment and Management (68 papers), Diabetes Management and Research (58 papers) and Pancreatic function and diabetes (23 papers). Carol Wysham collaborates with scholars based in United States, United Kingdom and Canada. Carol Wysham's co-authors include Richard M. Bergenstal, Julio Rosenstock, Ping Yan, Jaret Malloy, Brandon Walsh, Leigh MacConell, Clare J. Lee, Huzhang Mao, Chrisanthi A. Karanikas and Juan P. Frías and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Carol Wysham

73 papers receiving 2.9k citations

Hit Papers

Efficacy and safety of a ... 2010 2026 2015 2020 2021 2010 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
    2021 648 citations Julio Rosenstock, Carol Wysham et al. The Lancet profile →
  2. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
    2010 510 citations Richard M. Bergenstal, Carol Wysham et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carol Wysham United States 23 2.6k 1.0k 922 635 344 77 3.1k
Eleni Bekiari Greece 23 2.2k 0.8× 914 0.9× 969 1.1× 482 0.8× 313 0.9× 72 2.8k
Serge Jabbour United States 28 2.3k 0.9× 1.1k 1.0× 896 1.0× 428 0.7× 261 0.8× 78 3.0k
Murray Stewart United Kingdom 31 2.2k 0.8× 1.2k 1.2× 975 1.1× 442 0.7× 358 1.0× 68 3.1k
Laura Fernández Landó United States 18 2.6k 1.0× 1.1k 1.1× 754 0.8× 990 1.6× 763 2.2× 52 3.2k
M. Nauck Germany 3 2.8k 1.1× 1.1k 1.1× 828 0.9× 284 0.4× 309 0.9× 5 3.3k
Thomas Blevins United States 23 2.3k 0.9× 724 0.7× 954 1.0× 441 0.7× 216 0.6× 55 2.6k
Curtis Triplitt United States 30 1.8k 0.7× 1.1k 1.0× 834 0.9× 246 0.4× 527 1.5× 89 2.7k
Freddy G. Eliaschewitz Brazil 17 1.6k 0.6× 735 0.7× 640 0.7× 386 0.6× 174 0.5× 43 2.1k
Xuewei Cui United States 16 2.9k 1.1× 1.5k 1.4× 1.1k 1.2× 1.2k 1.8× 865 2.5× 37 3.8k
Zvonko Miličević United States 26 3.7k 1.4× 1.6k 1.5× 1.2k 1.3× 1.3k 2.0× 938 2.7× 83 4.5k

Countries citing papers authored by Carol Wysham

Since Specialization
Citations

This map shows the geographic impact of Carol Wysham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Wysham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Wysham more than expected).

Fields of papers citing papers by Carol Wysham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Wysham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Wysham. The network helps show where Carol Wysham may publish in the future.

Co-authorship network of co-authors of Carol Wysham

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Wysham. A scholar is included among the top collaborators of Carol Wysham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Wysham. Carol Wysham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wysham, Carol, et al.. (2025). A systematic literature review on the burden of diabetic ketoacidosis in type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 27(5). 2750–2767. 6 indexed citations
2.
Block, Christophe De, John Wilding, Anita Y. M. Kwan, et al.. (2024). Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics. Diabetes Therapy. 16(1). 43–71. 4 indexed citations
3.
Bergenstal, Richard M., Athena Philis‐Tsimikas, Carol Wysham, et al.. (2024). Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme. Diabetes Obesity and Metabolism. 26(8). 3020–3030. 11 indexed citations
4.
5.
6.
Block, Christophe De, et al.. (2022). Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. Diabetes Obesity and Metabolism. 25(1). 3–17. 71 indexed citations
7.
Chen, Yun, Dana K. Sindelar, Trang T. Ly, et al.. (2021). The Effect of Prestudy Insulin Therapy on Safety and Efficacy of Human Regular U-500 Insulin by Pump or Injection: A Posthoc Analysis. Endocrine Practice. 27(8). 783–789. 1 indexed citations
8.
Rosenstock, Julio, Carol Wysham, Juan P. Frías, et al.. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 398(10295). 143–155. 648 indexed citations breakdown →
9.
Young, James B., Marjolaine Gauthier‐Loiselle, Robert A. Bailey, et al.. (2018). Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data. Cardiovascular Diabetology. 17(1). 118–118. 31 indexed citations
10.
Wysham, Carol, Patrick Lefèbvre, Dominic Pilon, et al.. (2018). An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records. Journal of Diabetes and its Complications. 33(2). 140–147. 6 indexed citations
11.
Wysham, Carol, Dominic Pilon, Marie‐Hélène Lafeuille, et al.. (2018). Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting. Current Medical Research and Opinion. 34(6). 1125–1133. 8 indexed citations
12.
Philis‐Tsimikas, Athena, Carol Wysham, Elise Hardy, Jenny Han, & Nayyar Iqbal. (2018). Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study. Journal of Diabetes and its Complications. 33(3). 223–230. 22 indexed citations
13.
Wysham, Carol, Patrick Lefèbvre, Dominic Pilon, et al.. (2017). Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. BMC Endocrine Disorders. 17(1). 32–32. 4 indexed citations
14.
Wysham, Carol, Leigh MacConell, David Maggs, et al.. (2015). Five-Year Efficacy and Safety Data of Exenatide Once Weekly. Mayo Clinic Proceedings. 90(3). 356–365. 47 indexed citations
15.
Wysham, Carol, Thomas Blevins, Richard F. Arakaki, et al.. (2014). Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care. 37(8). 2159–2167. 321 indexed citations
16.
Bloomgarden, Zachary T., Lawrence Blonde, Alan J. Garber, & Carol Wysham. (2012). Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes. Endocrine Practice. 18. 6–26. 3 indexed citations
17.
O’Connor, Patrick J., Noni L. Bodkin, Judith Fradkin, et al.. (2011). Consensus Report: Diabetes Performance Measures: Current Status and Future Directions. Clinical Diabetes. 29(3). 102–112. 3 indexed citations
18.
Wysham, Carol, Richard M. Bergenstal, Jaret Malloy, et al.. (2011). DURATION‐2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once‐weekly exenatide. Diabetic Medicine. 28(6). 705–714. 101 indexed citations
19.
Blank, Sally E., et al.. (2010). Circulating dendritic cell number and intracellular TNF-α production in women with type 2 diabetes. Acta Diabetologica. 49(S1). 25–32. 24 indexed citations
20.
Kathol, Roger G., et al.. (1992). Imipramine effect on hypothalamic-pituitary-adrenal axis response to hypoglycemia. Psychiatry Research. 41(1). 45–52. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eleni Bekiari Breakdown of academic impact, for papers by Serge Jabbour Breakdown of academic impact, for papers by Murray Stewart Breakdown of academic impact, for papers by Laura Fernández Landó Breakdown of academic impact, for papers by M. Nauck Breakdown of academic impact, for papers by Thomas Blevins Breakdown of academic impact, for papers by Curtis Triplitt Breakdown of academic impact, for papers by Freddy G. Eliaschewitz Breakdown of academic impact, for papers by Xuewei Cui Breakdown of academic impact, for papers by Zvonko Miličević
Rankless by CCL
2026